tradmap

CME Financials CME Group

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 6.0% per year over the past 5 years.
  • Net income has grown faster than revenue (14.1% vs 6.0% per year).
  • Operating margin has expanded, at 64.9% in the latest year.
  • Free cash flow has grown 10.7% per year over the past 5 years.

Financial health

  • Operating income covered interest expense 24× in the latest year, up from 16× 5 years ago.

Shareholder returns

  • Dividends have been paid for 15 consecutive years, consuming 96.6% of earnings and 93.8% of free cash flow.
  • The dividend has grown 13.3% per year over the past 5 years.
Revenue & net income
$0 $3B $7B 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 56% 111% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $2B $4B 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $2B $4B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$48B $11B $70B $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $6.5B $4.1B 0.0% 64.9% $4.2B $4.4B
2024 $6.1B $3.5B 0.0% 64.1% $3.6B $2.9B
2023 $5.6B $3.2B 0.0% 61.6% $3.4B $2.9B
2022 $5.0B $2.7B 0.0% 60.1% $3.0B $2.7B
2021 $4.7B $2.6B 0.0% 56.4% $2.3B $2.8B
2020 $4.9B $2.1B 0.0% 54.0% $2.5B $1.6B
2019 $4.9B $2.1B 0.0% 53.2% $2.4B $1.6B
2018 $4.3B $2.0B 0.0% 60.5% $2.3B $1.4B
2017 $3.6B $4.1B 0.0% 63.4% $1.7B $1.9B
2016 $3.6B $1.5B 0.0% 61.2% $1.6B $1.9B
2015 $3.3B $1.2B 0.0% 59.8% $1.4B $1.7B
2014 $3.1B $1.1B 0.0% 56.8% $1.2B $1.4B
2013 $2.9B $977M 0.0% 55.8% $1.2B $2.5B
2012 $2.9B $896M 0.0% 58.1% $1.1B $1.6B
2011 $3.3B $1.8B 0.0% 61.6% $1.2B $1.0B

Valuation over time

How the market has priced CME against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 14.7 29.4 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 8.8 17.6 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S
Dividend yield (%)
0.0 2.4 4.9 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
Dividend yield %

Frequently asked questions

Is CME growing its revenue and profit?

Over the past 5 years, CME Group's revenue has grown 6.0% per year, and net income grown 14.1% per year. These are computed facts, not advice.

How much debt does CME have?

As of FY2025, CME Group reported — of total debt against $4.4B of cash; operating income covered interest expense 24×.

What is CME's profit margin?

In FY2025, gross margin was —, operating margin 64.9%, and net margin 62.5%.

What is CME's P/E ratio?

As of Jun '26, CME Group traded at a price-to-earnings ratio of about 19.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.